REDX vs. ETX, TRX, POLB, AREC, C4XD, SCLP, SAR, OBD, HEMO, and OPTI
Should you be buying Redx Pharma stock or one of its competitors? The main competitors of Redx Pharma include e-therapeutics (ETX), Tissue Regenix Group (TRX), Poolbeg Pharma (POLB), Arecor Therapeutics (AREC), C4X Discovery (C4XD), Scancell (SCLP), Sareum (SAR), Oxford BioDynamics (OBD), Hemogenyx Pharmaceuticals (HEMO), and OptiBiotix Health (OPTI). These companies are all part of the "biotechnology" industry.
Redx Pharma (LON:REDX) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership.
e-therapeutics has lower revenue, but higher earnings than Redx Pharma. e-therapeutics is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.
72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 26.5% of e-therapeutics shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by insiders. Comparatively, 59.4% of e-therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Redx Pharma received 25 more outperform votes than e-therapeutics when rated by MarketBeat users. Likewise, 73.56% of users gave Redx Pharma an outperform vote while only 60.09% of users gave e-therapeutics an outperform vote.
e-therapeutics' return on equity of -38.75% beat Redx Pharma's return on equity.
In the previous week, e-therapeutics had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for e-therapeutics and 0 mentions for Redx Pharma. e-therapeutics' average media sentiment score of 1.15 beat Redx Pharma's score of -0.21 indicating that e-therapeutics is being referred to more favorably in the news media.
Redx Pharma has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, e-therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
Summary
e-therapeutics beats Redx Pharma on 9 of the 14 factors compared between the two stocks.
Get Redx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for REDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Redx Pharma Competitors List
Related Companies and Tools
